Anthracycline Cardiotoxicity: Strategies for Prevention and Intervention

Crossmark: check for updates

Authors

  • Chang H. Kim Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH, USA; School of Medicine, Case Western Reserve University, Cleveland, OH, USA
  • Sadeer Al-Kindi Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH, USA; School of Medicine, Case Western Reserve University, Cleveland, OH, USA
  • Guilherme H. Oliveira Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH, USA; School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleve-land, OH, USA

DOI:

https://doi.org/10.17140/HROJ-2-e004

Keywords:

Anthracycline cardiotoxicity, Echocardiography, Strain imaging, Global longitudinal strain

Abstract

The cardiotoxic effects of anthracycline compounds, used extensively to treat malignancies
such as breast cancer and lymphoma, are well known.1,2 However, despite efforts
towards cardioprotective strategies and early detection of anthracycline cardiotoxicity, defined
as decline in Left Ventricular Ejection Fraction (LVEF) of ≥10% from baseline or to <50%,3,4
there is currently no consensus on the optimal approach. Current clinical practice guidelines
recommend serial LVEF monitoring to identify cardiotoxicity in high-risk patients receiving
anthracyclines;3,4 however, it has come to light that LVEF reduction may be a late manifestation
of cardiotoxicity,5,6 with potentially limited prospects for reversibility.7-9 Recently, echocardiographic
strain imaging has emerged as a promising way to detect subclinical cardiotoxicity prior
to LVEF reduction,10-13 where small reduction in Global Longitudinal Strain (GLS) has been
identified as a robust predictor of future LVEF reduction and cardiac events.14-16 The reliability
of this approach in patients treated with anthracyclines has been specifically evaluated,17-19 with
reported cardiotoxicity rates ranging from <1% to 32%.20 Recent studies have established a
GLS reduction of ≥11% as a strong predictor of cardiotoxicity.19,21-24

References

Al-Kindi S, Younes A, Qattan M, Oliveira GH. Preemptive cardioprotective strategies in patients receiving chemotherapy. Curr Cardiovasc Risk Rep. 2014; 8: 406. doi: 10.1007/s12170-014-0406-5

Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportuinities. J Am Coll Cardiol. 2014; 64(9): 938-945. doi: 10.1016/j.jacc.2014.06.1167

Hensley ML, Hagerty KL, Kewalramani T, et al. American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27(1): 127-145. doi: 10.1200/ JCO.2008.17.2627

Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012; 23(Suppl 7): 7155-7166. doi: 10.1093/annonc/mds293

Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13:699-709. doi: 10.1093/annonc/mdf132

Manisty CH, Francis DP. Ejection fraction: ameasure of desperation? Heart. 2008; 94: 400-401. doi: 10.1136/hrt.2007.118976

Oliveira GH, Mukerji S, Hernandez AV, et al. Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. Am J Cardiol. 2014; 113(11): 1893-1898. doi: 10.1016/j.amjcard.2014.03.018

Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharma-cologic therapy. J Am Coll Cardiol. 2010; 55: 213-220. doi: 10.1016/j.jacc.2009.03.095

Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of revers-ibility. J Clin Oncol. 2007; 25: 3525-3533. doi: 10.1200/JCO.2007.11.0106

Abraham TP, Dimaano VL, Liang HY. Role of tissue doppler and strain echocardiography in current clinical practice. Circula-tion. 2007; 116(22): 2597-2609. doi: 10.1161/CIRCULATIONAHA.106.647172

Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011; 107: 1375-1380.

Stoodley PW, Richards DA, Hui R, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging. 2013; 14: 228-334. doi: 10.1093/ehjci/ jes139

Tsai HR, Gjesdal O, Wethal T, et al. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin’s lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Am J Cardiol. 2011; 107: 472-477. doi: 10.1016/j.amjcard.2010.09.048

Mele D, Rizzo P, Pollina AV, Fiorencis A, Ferrari R. Cancer therapy-induced cardiotoxicity: role of ultrasound deformation im-aging as an aid to early diagnosis. Ultrasound Med Biol. 2014; 41(3): 627-641. doi: 10.1016/j.ultrasmedbio.2014.11.015

Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014; 100: 1673-1680. doi: 10.1136/heartjnl-2014-305538

Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013; 26: 493-498. doi: 10.1016/j.echo.2013.02.008

Mavinkurve-Groothuis AM, Marcus KA, Pourier M, et al. Myocardial 2-D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2013; 14: 562-569. doi: 10.1093/ehjci/jes217

Kang Y, Cheng L, Li L, et al. Early detection of anthracycline-induced cardiotoxicity using two dimensional speckle tracking echocardiography. Cardiol J. 2013; 20: 592-599. doi: 10.5603/CJ.2013.0158

Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotox-icity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012; 5: 596-603. doi: 10.1161/ CIRCIMAGING.112.973321

Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy-a systematic review. J Am CollCardiol. 2014; 63(25): 2751-2768. doi: 10.1016/j.jacc.2014.01.073

Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014; 15: 324-331. doi: 10.1093/ehjci/jet159

Baratta S, Damiano M, Marchese M, et al. Serum markers, conventional doppler echocardiography and two-dimensional sys-tolic strain in the diagnosis of chemotherapy-induced myocardial toxicity. Rev Argent Cardiol. 2013; 81: 151-158.

Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudi-nal left ventricular strain and twist. Can J Physiol Pharmacol. 2013; 91: 601-607. doi: 10.1139/cjpp-2012-0398

Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor recep-tor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011; 57: 2263-2270. doi: 10.1016/j. jacc.2010.11.063

Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic re-view and meta-analysis. Eur J Cancer. 2013; 49: 2900-2909. doi: 10.1016/j.ejca.2013.04.030

Yun S, Vincelette ND, Abraham I. Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracy-clines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J. 2015; 91(1081): 627-633. doi: 10.1136/postgradmedj-2015-133535

Heck SL, Gulati G, Ree AH, et al. Rational and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial. Cardiology. 2012; 123(3): 240-247. doi: 10.1159/000343622

Gulati G, Heck SL, Ree HR, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2x2 factorial, placebo-controlled, double-blind clinical trial. www.clinicaltrialresults.org/Slides/AHA2015/ Gulati_PRADA.ppt

Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003; 82(4): 218-222. doi: 10.1007/s00277-003-0615-3

Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000; 36(2): 517-522. doi: 10.1016/S0735-1097(00)00748-8

Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin converting enzyme inhibition. Circulation. 2006; 114: 2474-2481. doi: 10.1161/CIRCULATIONAHA.106.635144

Koseoglu V, Berberoglu S, Karademir S, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin? Turk J Pediatr. 2005; 47(1): 17-22.

Mathew P, SuarezW, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? a pilot study. Cancer Investig. 2001; 19(4): 352-359. doi: 10.1081/CNV-100103130

Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res Off J Am Assoc Cancer Res. 2011; 17(10): 3490-3499. doi: 10.1158/1078-0432.CCR-10-1359

Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. J Am Coll Cardiol. 2013; 61(23): 2355-2362. doi: 10.1016/j.jacc.2013.02.072

Downloads

Published

2015-11-16

How to Cite

Chang H. Kim, Sadeer Al-Kindi, & Guilherme H. Oliveira. (2015). Anthracycline Cardiotoxicity: Strategies for Prevention and Intervention. Heart Research, 2(4), e9-e12. https://doi.org/10.17140/HROJ-2-e004

Issue

Vol. 2 No. 4 (2015): Volume 2 Issue 4 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.